in the news, Prosetta:
Concludes in-licensing agreement with UCSF Closes Series A round of Convertible Preferred Stock Opens first research lab In-licenses IP from Chiron for Hepatitis C research Enters a joint research and development agreement with SUNY Buffalo / CUBRC Closes Series AA round of Convertible Preferred Stock Signs contract to conduct anti-viral research for US DoD (NOVBAIT I) Opens new lab and office in San Francisco, SOMA near Mission Bay Signs new DoD contract for medical research (TMTI) Awarded contract for continuation and expansion of anti-viral research (NOVBAIT II) Announces Prosetta Bioconformatics Ltd. as a wholly owned subsidiary
Concludes in-licensing agreement with UCSF
Closes Series A round of Convertible Preferred Stock
Opens first research lab
In-licenses IP from Chiron for Hepatitis C research
Enters a joint research and development agreement with SUNY Buffalo / CUBRC
Closes Series AA round of Convertible Preferred Stock
Signs contract to conduct anti-viral research for US DoD (NOVBAIT I)
Opens new lab and office in San Francisco, SOMA near Mission Bay
Signs new DoD contract for medical research (TMTI)
Awarded contract for continuation and expansion of anti-viral research (NOVBAIT II)
Announces Prosetta Bioconformatics Ltd. as a wholly owned subsidiary
Our Company | Our Science | Our News | Our Team | Contact Us
©All rights reserved, Prosetta Corporation.
